Organon en las noticias
Terapias y productos sanitarios
Tamtam encontró 20 artículos recientes sobre Organon.
- Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
- Henlius
- Sun Pharma completes $11.75bn financing syndication for Organon acquisition
- Organon & Co. Shareholders Clear Sun Pharma Merger Deal
- Organon commits more than $1.3 million towards enabling choices and resilient demographies with UNFPA
- Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
- White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon
- Sun Pharma to buy Organon for more than $11 billion
- Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
- Organon: Deep Value With No Clear Catalysts (NYSE:OGN)
- Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts
- TetraScience and Organon Collaborate to Modernize Quality Control Data Management
- Laborie Expands Portfolio with Acquisition of JADA System from Organon
- Organon Details Nexplanon Sales Practice Issue
- Organon CEO exits, company goes on hunt for successor as internal probe turns up 'improper' Nexplanon sales tactics
- Organon divests Jada System, sends 100 employees to Laborie Medical Technologies in $465M deal
- Organon and Henlius see FDA approval of Poherdy for HER2-positive breast cancers
- Organon and UNFPA advance reproductive health services
- Henlius, Organon win US FDA approval of first Perjeta biosimilar
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Organon?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares